The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis
Open accessAbstract
Background— Treatment of in-stent restenosis with paclitaxel-coated balloon catheter as compared with plain balloon angioplasty has shown surprisingly low late lumen loss at 6 months and fewer major adverse cardiac events up to 2 years. We compared the efficacy and safety of a paclitaxel-coated balloon with a paclitaxel-eluting stent as the current standard of care. Methods and Results— One hundred thirty-one patients with coronary in-stent restenosis were randomly assigned to treatment by a paclitaxel-coated balloon (3 μg/mm 2 ) or a paclitaxel-eluting stent. The main inclusion criteria encompassed diameter stenosis of ≥70% and ≤22 mm in length, with a vessel diameter of 2.5 to 3.5 mm. The primary end point was angiographic in-segment late lumen loss. Quantitative coronary angiography revealed no differences in baseline parameters. At 6 months follow-up, in-segment late lumen loss was 0.38±0.61 mm in the drug-eluting stent group versus 0.17±0.42 mm ( P =0.03) in the drug-coated balloon group, resulting in a binary restenosis rate of 12 of 59 (20%) versus 4 of 57 (7%; P =0.06). At 12 months, the rate of major adverse cardiac events were 22% and 9%, respectively ( P =0.08). This difference was primarily due to the need for target lesion revascularization in 4 patients (6%) in the coated-balloon group, compared with 10 patients (15%) in the stent group ( P =0.15). Conclusions— Treatment of coronary in-stent restenosis with the paclitaxel-coated balloon was at least as efficacious and as well tolerated as the paclitaxel-eluting stent. For the treatment of in-stent restenosis, inhibition of re-restenosis does not require a second stent implantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Iakovou, I. (2005) · JAMA · doi:10.1001/jama.293.17.2126 · Cited by 3,132
Pathology of Drug-Eluting Stents in Humans
Joner, M., Finn, A. V., Farb, A., Mont, E. K., Kolodgie, F. D., Ladich, E., Kutys, R., Skorija, K., Gold, H. K., & Virmani, R. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.042 · Cited by 2,744
Abraham, J. (2010) · Handbook of Transnational Economic Governance Regimes · doi:10.1163/ej.9789004163300.i-1081.897 · Cited by 2,582
Daemen, J., Wenaweser, P., Tsuchida, K., Abrecht, L., Vaina, S., Morger, C., Kukreja, N., Jüni, P., Sianos, G., Hellige, G., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60314-6 · Cited by 1,757
Virmani, R., Guagliumi, G., Farb, A., Musumeci, G., Grieco, N., Motta, T., Mihalcsik, L., Tespili, M., Valsecchi, O., & Kolodgie, F. D. (2004) · Circulation · doi:10.1161/01.cir.0000116202.41966.d4 · Cited by 1,469
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents
Pfisterer, M., Brunner-La Rocca, H. P., Buser, P. T., Rickenbacher, P., Hunziker, P., Mueller, C., Jeger, R., Bader, F., Osswald, S., & Kaiser, C. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.026 · Cited by 1,303
Angiographic Patterns of In-Stent Restenosis: Classification and Implications for Long-Term Outcome
Mehran, R., Dangas, G., Abizaid, A. S., Mintz, G. S., Lansky, A. J., Satler, L. F., Pichard, A. D., Kent, K. M., Stone, G. W., & Leon, M. B. (1999) · Circulation · doi:10.1161/01.cir.100.18.1872 · Cited by 1,258
Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden
Lagerqvist, B., James, S. K., Stenestrand, U., Lindbäck, J., Nilsson, T., & Wallentin, L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067722 · Cited by 1,197
Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon Catheter
Scheller, B., Hehrlein, C., Bocksch, W., Rutsch, W., Haghi, D., Dietz, U., Böhm, M., & Speck, U. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061254 · Cited by 816
Self-citationLocal Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg
Tepe, G., Zeller, T., Albrecht, T., Heller, S., Schwarzwälder, U., Beregi, J.-P., Claussen, M. D. C. D., Oldenburg, A., Scheller, B., & Speck, U. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706356 · Cited by 803
Self-citationAxel, D. I., Kunert, W., Göggelmann, C., Oberhoff, M., Herdeg, C., Küttner, A., Wild, D. H., Brehm, B. R., Riessen, R., Köveker, G., et al. (1997) · Circulation · doi:10.1161/01.cir.96.2.636 · Cited by 784
A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
Spaulding, C., Daemen, J., Boersma, E., Cutlip, D. E., & Serruys, P. W. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066633 · Cited by 704
Kastrati, A., Mehilli, J., von Beckerath, N., Dibra, A., Hausleiter, J., Pache, J., Schühlen, H., Schmitt, C., Dirschinger, J., Schömig, A., et al. (2005) · JAMA · doi:10.1001/jama.293.2.165 · Cited by 605
Werk, M., Langner, S., Reinkensmeier, B., Boettcher, H.-F., Tepe, G., Dietz, U., Hosten, N., Hamm, B., Speck, U., & Ricke, J. (2008) · Circulation · doi:10.1161/circulationaha.107.735985 · Cited by 511
Self-citationDuda, S. H., Pusich, B., Richter, G., Landwehr, P., Oliva, V. L., Tielbeek, A., Wiesinger, B., Hak, J. B., Tielemans, H., Ziemer, G., et al. (2002) · Circulation · doi:10.1161/01.cir.0000029746.10018.36 · Cited by 446
Physiological Transport Forces Govern Drug Distribution for Stent-Based Delivery
Hwang, C.-W., Wu, D., & Edelman, E. R. (2001) · Circulation · doi:10.1161/hc3101.092214 · Cited by 426
Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo
Herdeg, C., Oberhoff, M., Baumbach, A., Blattner, A., Axel, D. I., Schröder, S., Heinle, H., & Karsch, K. R. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00614-8 · Cited by 276
Cited by
2018 ESC/EACTS guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy394 · Cited by 7,167
(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
2014 ESC/EACTS Guidelines on myocardial revascularization
Kolh, P., Windecker, S., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu366 · Cited by 4,199
Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), Authors/Task Force Members, Wijns, W., Kolh, P., Danchin, N., Di Mario, C., Falk, V., Folliguet, T., Garg, S., Huber, K., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq277 · Cited by 3,184
2018 ESC/EACTS Guidelines on myocardial revascularization
Neumann, F.-J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., Byrne, R. A., Collet, J.-P., Falk, V., Head, S. J., et al. (2019) · EuroIntervention · doi:10.4244/eijy19m01_01 · Cited by 1,259
Metadata
- Authors
- Unverdorben, M., Vallbracht, C., Cremers, B., Heuer, H., Hengstenberg, C., Maikowski, C., Werner, G. S., Antoni, D., Kleber, F. X., Bocksch, W., Leschke, M., Ackermann, H., Boxberger, M., Speck, U., Degenhardt, R., & Scheller, B.
- Venue
- Circulation
- Published
- 2009-06-16
- Volume
- 119
- Issue
- 23
- Pages
- 2986-2994
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2109769695
- Cited by
- 511
- References
- 19
- FWCI
- 46.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.